James Healy
At a glance: James Healy is Director at Rapport Therapeutics (RAPP). Their latest SEC Form 4, filed Oct 30, 2026, reported a purchase of $20.0M. On file: 4 purchase lines ($20.4M) and 0 sale lines ($0).
Director at Rapport Therapeutics, Inc. (RAPP)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Every purchase since 2021
From the SEC's insider data sets: each open-market buy by James Healy, matched to how the stock did over the next 90 days against the S&P 500.
1 of 1 buy beat the S&P 500 (100%), median +0.9% vs. the index. Small sample: treat with care. All insider buys: 46%.
| Stock | Filed | 90 days vs. S&P 500 |
|---|---|---|
| NTRA | Jul 26, 2021 | +0.9% |
Buys made close together in one stock count once. Price-only returns; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 30 NewSEC | RAPPRapport Therapeutics, Inc. | Buy | 952,3802,815,707 held (+51%) | $21.00 | $20.0M | +20.0% |
| Oct 30 NewSEC | RAPPRapport Therapeutics, Inc. | Buy | 6,39517,990 held (+55%) | $21.00 | $134K | +20.0% |
| Oct 30 NewSEC | RAPPRapport Therapeutics, Inc. | Buy | 3,77214,924 held (+34%) | $21.00 | $79K | +20.0% |
| Oct 30 NewSEC | RAPPRapport Therapeutics, Inc. | Buy | 6,93325,267 held (+38%) | $21.00 | $146K | +20.0% |
- Buy
Director James Healy bought $20.0M of RAPP at $21.00 — first open-market purchase in our records; raises the stake by 51%.
- Buy
Director James Healy bought $134K of RAPP at $21.00 — raises the stake by 55%.
- Buy
Director James Healy bought $79K of RAPP at $21.00 — raises the stake by 34%.
- Buy
Director James Healy bought $146K of RAPP at $21.00 — raises the stake by 38%.